HER2/PD-L1 BsAb (Dartsbio Pharmaceuticals)

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameHER2/PD-L1 BsAb (Dartsbio Pharmaceuticals)
Drug Alias NameHER2/PD-L1 BsAb (Dartsbio Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A